Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression.
about
Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted TherapyClinical and genetic predictors of prognosis in myelodysplastic syndromes.From the Biology of PP2A to the PADs for Therapy of Hematologic MalignanciesSETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis.Overlapping SETBP1 gain-of-function mutations in Schinzel-Giedion syndrome and hematologic malignancies.Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series.Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemiaDynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome.Exploration of the role of gene mutations in myelodysplastic syndromes through a sequencing design involving a small number of target genes.Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).-7/7q- syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity.The molecular pathogenesis of the myelodysplastic syndromes.Somatic SETBP1 mutations in myeloid neoplasms.Clinico-biological significance of suppressor of cytokine signaling 1 expression in acute myeloid leukemia.Genome-wide association study of antibody level response to NDV and IBV in Jinghai yellow chicken based on SLAF-seq technology.SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms.Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignancies.Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R.Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis.Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes.Therapy-associated myelodysplastic syndrome with monosomy 7 arising in a Muir-Torre Syndrome patient carrying SETBP1 mutation.Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome.SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution.Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome.Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.SRSF2 mutations in myelodysplasia/myeloproliferative neoplasmsGATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia
P2860
Q26749870-1960EF72-97B5-4119-BC80-E93901BFC82EQ33695906-824A8A9D-F427-48C0-96C2-24DA3B5D92DAQ34043449-8D4F18F3-BCCE-48A2-9EF0-55A9640963BDQ35849733-C809AEC5-6635-439F-B940-0265815C3689Q35921904-F0E188F7-855D-4CE4-9F8A-5D991469DF12Q36270003-B1756439-1243-4834-8E12-95EBD8EFD23EQ36323864-7E0F2C6E-8404-4B2D-AF27-16429367F1CCQ36693223-1A803756-EDA2-4094-B04C-549DC07F9F40Q36962514-B71334CA-806E-4C2C-AD72-D58E669747EBQ37555315-3D5AA23F-024E-463C-A133-1B603E44ED3FQ37654921-055F2782-4A11-4CA2-805B-16F0C55040F0Q37665288-DA465E6B-D0C5-4167-96B5-C6DB77D3C021Q38226741-76C4C8F3-44C4-464B-BA44-A7E0E1277B10Q38341998-19DC9EFB-CDD0-4265-B459-FE9C9E2EE900Q39266051-ACCC8F5B-D403-4869-9E7F-3D78A2BBE1C4Q41316658-D389E446-8E7A-471F-A68B-20D940446F85Q41545001-2FF932E8-7E42-4120-9893-DE8BE3F66E1AQ43135315-B2148244-297B-4FA6-88F8-6CE8C7663F39Q47797877-B1FBA0C9-F05F-4196-84CE-3F5B94AD6521Q48123200-777730AC-8B83-444A-B998-952CC9B83C2AQ48316140-CF43E23C-23BC-448F-ACAF-FB6BD23B3B96Q48730157-4D298364-B1D9-426C-A375-13D277EEFDD3Q50052553-F439DFF2-B38E-44FD-8B63-2D123DF147E1Q52721521-DEB82F93-19EE-43D0-9474-09B6AE220F35Q53058458-C7D9858C-5E00-41DC-A6EE-E63EF74E0AC5Q55009819-2192E001-8588-4597-A4BA-ABCEE5D8E030Q55025720-B2A76743-988E-4E15-B046-D69AD81FB781Q57069030-1189959B-1AFA-4CA2-B9AC-3D66872B6449Q58781139-B15D44C2-7C19-4E8E-B35A-05B18D398B6C
P2860
Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Clinical implications of the S ...... ty during disease progression.
@en
Clinical implications of the S ...... ty during disease progression.
@nl
type
label
Clinical implications of the S ...... ty during disease progression.
@en
Clinical implications of the S ...... ty during disease progression.
@nl
prefLabel
Clinical implications of the S ...... ty during disease progression.
@en
Clinical implications of the S ...... ty during disease progression.
@nl
P2093
P2860
P50
P356
P1476
Clinical implications of the S ...... ity during disease progression
@en
P2093
Chi-Fei Huang
Chia-Wen Liu
Chieh-Yu Liu
Chien-Yuan Chen
Fen-Yu Lee
Mei-Hsuan Tseng
Ming-Chih Liu
Shang-Ju Wu
Shang-Yi Huang
P2860
P304
P356
10.1002/AJH.23611
P50
P577
2013-11-20T00:00:00Z